

600954
FORM
REGULATION 9

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952-1973

APPLICATION FOR A PATENT

I/We **MEDIOLANUM FARMACEUTICI S.r.l.**

of **Via S. Giuseppe Cottolengo 31, 20100 MILAN, ITALY**

hereby apply for the grant of a Patent for an invention entitled:

**HIGHLY SOLUBLE ANTIBACTERIALLY ACTIVE ORGANIC SALTS OF
PYRIDOBENZOTHAZINES AND THEIR PREPARATION PROCESS**

which is described in the accompanying complete specification. This Application is a Convention Application and is based on the Application(s) numbered: 20997 A/86 for a Patent or similar protection made in Italy on 1 July 1986.

APPLICATION ACCEPTED AND AMENDMENTS

My/Our address for service is:

ALLOWED

21.6.90

**GRIFFITH HASSEL & FRAZER
71 YORK STREET
SYDNEY N.S.W. 2000
AUSTRALIA**


DATED this 29th day of June, 1987.

MEDIOLANUM FARMACEUTICI S.r.l.

By his/their Patent Attorneys

GRIFFITH HASSEL & FRAZER

TO: THE COMMISSIONER OF PATENTS
COMMONWEALTH OF AUSTRALIA
9149A:rk



AUSTRALIA
PATENTS ACT 1952 (AS AMENDED)
DECLARATION IN SUPPORT OF AN APPLICATION FOR A PATENT

(Name of applicant)

In support of an Application made by: **MEDIOLANUM FARMACEUTICI S.r.l.**

(Title)

for a patent for an invention entitled:
**HIGHLY SOLUBLE ANTIBACTERIALLY ACTIVE ORGANIC SALTS
OF PYRIDOBENZOTHAZINES AND THEIR PREPARATION PROCESS**

(Full name of and address of signatory)

I, **Mr. Brasca**
of, **via S. Giuseppe Cottolengo 31, 20100 Milan, ITALY**

do solemnly and sincerely declare as follows:

1. I am authorised by the above mentioned applicant for the patent to make this Declaration on its behalf.
2. The name and address of each actual inventor of the invention is as follows: **Patrizia Terni ; Pier Luigi Rugarli; Stefano Maiorana; Pier Giuseppe Pagella and Raffaello Fusco**
of **via Lodovico Il Moro 57, Milan; Via Chopin 89 Milan; Via Don C. Porro 6, Milan; Isola S. Antonio, Fraz. Capraglia 56, Alessandria and Via Sismondi 6, Milan, respectively**
and the fact(s) upon which the applicant is entitled to make this application are as follows:
The applicant is the assignee of the said invention from the said inventors
3. The basic application(s) as defined by Section 141 of the Act was(were) made as follows:
Country **Italy** on **1 July 1986**
in the name(s) **Mediolanum Farmaceutici S.r.l.**
and in on
in the name(s)
and in on
in the name(s)
4. The basic application(s) referred to in the preceding paragraph of this Declaration was(were) the first application(s) made in a Convention country in respect of the invention the subject of this application.

(Place and date of signing)

Declared at **Milan, Italy** this **16th** day of **June**, 19**87**

Signed: **MEDIOLANUM**

Position: **farmaceutici**

GRIFFITH, HASSEL & FRAZER, SYDNEY, AUSTRALIA

(12) PATENT ABRIDGMENT (11) Document No. AU-B-74929/87
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 600954

- (54) Title
ANTIBACTERIAL SALTS OF PYRIDOBENZOTHAZINES
- International Patent Classification(s)
(51)⁴ C07D 513/06 A61K 031/54
- (21) Application No. : 74929/87 (22) Application Date : 29.06.87
- (30) Priority Data
- (31) Number (32) Date (33) Country
20997 /86 01.07.86 IT ITALY
- (43) Publication Date : 07.01.88
- (44) Publication Date of Accepted Application : 30.08.90
- (71) Applicant(s)
MEDIOILANUM FARMACEUTICI S.R.L.
- (72) Inventor(s)
PATRIZIA TERNI; PIER LUIGI RUGARLI; STEFANO MAIORANA; PIER GIUSEPPE
PAGELLA; RAFFAELLO FUSCO
- (74) Attorney or Agent
GRIFFITH HACK & CO. SYDNEY
- (56) Prior Art Documents
AU 599829 21718/88 C07D 513/06 498/06 A61K 031/535
AU 57640/87 C07D 401/10 401/04 498/06
AU 562237 50792/85 C07D 215/56 405/10 471/06
- (57) This invention relates to new highly soluble
antibacterially active salts of pyrido-benzothiazines with
organic acids.

CLAIM

1. Highly water-soluble, antibacterially active
organic acid salts of pyridobenzothiazines wherein the
pyridobenzothiazine is 9-fluoro-10[N-(4'-methyl)piperazinyl]
-7-oxo-2,3-dihydro-7H-pyrido[1.2,3 de][1,4]benzothiazine
-6-carboxylic acid, wherein the organic acid is a sulphonic
acid chosen from the group consisting of methanesulphonic
acid, ethanesulphonic acid, n-dodecanesulphonic acid,
p.toluenesulphonic acid, 1-octadecanesulphonic acid,
2-chloroethanesulphonic acid, 2-bromoethanesulphonic acid
and 3-hydroxy-propanesulphonic acids or, wherein the organic
acid is a carboxylic acid chosen from the group consisting
of citric acid, malonic acid, gluconic acid, malic acid,
lactic acid and L-tartaric acid.

(11) AU-B-74929/87
(10) 600954

-2-

11. A method of preparing a therapeutic composition possessing antibacterial activity comprising admixing an organic acid salt of a pyrido-benzothiazine as claimed in claim 1 with a pharmaceutically acceptable carrier.

14. A pharmaceutical product containing an organic acid salt of a pyrido-benzothiazine as claimed in claim 1 and a carrier therefor.

600954

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

Form 10

SUBSTITUTE COMPLETE SPECIFICATION

FOR OFFICE USE

Short Title:

Int. Cl:

Application Number:
Lodged:

Complete Specification-Lodged:
Accepted:
Lapsed:
Published:

This document contains the
amendments made under
Section 49 and is correct for
printing.

Priority:

Related Art:

TO BE COMPLETED BY APPLICANT

Name of Applicant: MEDIOLANUM FARMACEUTICI Srl
Address of Applicant: Via S. Giuseppe Cottolengo 31, 20100 MILAN,
ITALY
Actual Inventor: Patrizia Terni; Pier Luigi Rugarli; Stefano
Maiorana; Pier Giuseppe Pagella and Raffello
Fusco
Address for Service: GRIFFITH HASSEL & FRAZER
71 YORK STREET
SYDNEY NSW 2000
AUSTRALIA

Complete Specification for the invention entitled:

HIGHLY SOLUBLE ANTIBACTERIALLY ACTIVE
ORGANIC SALTS OF PYRIDOBENZOTHAZINES AND
THEIR PREPARATION PROCESS

The following statement is a full description of this
invention, including the best method of performing it known
to me/us:-

3249A:rk

This invention relates to new highly soluble antibacterially active salts of pyrido-benzothiazines with organic acids.

More precisely, the invention relates to organic salts
5 of 9-fluoro 10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H
-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid with
an organic acid chosen from the group consisting of
methanesulphonic acid, ethanesulphonic acid,
n-dodecanesulphonic acid, p.toluenesulphonic acid,
10 1-octadecanesulphonic acid, 2-chloro-ethanesulphonic acid,
2-bromo-ethanesulphonic acid, 3-hydroxy-propanesulphonic
acid, citric acid, malonic acid, gluconic acid, malic acid,
lactic acid and L-tartaric acid. The present invention
therefore provides highly water-soluble antibacterially
15 active organic salts of pyridobenzothiazines wherein the
pyridobenzothiazine is 9-fluoro-10[N-(4'-methyl)piperazinyl]
-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine
-6-carboxylic acid, wherein the organic acid is a sulphonic
acid chosen from the group consisting of methanesulphonic
20 acid, ethanesulphonic acid, n-dodecanesulphonic acid,
p.toluenesulphonic acid, 1-octadecanesulphonic acid,
2-chloroethanesulphonic acid, 2-bromoethanesulphonic acid
and 3-hydroxy-propanesulphonic acid, or wherein the organic
acid is a carboxylic acid chosen from the group consisting
25 of citric acid, malonic acid, gluconic acid, malic acid,
lactic acid and L-tartaric acid.

It has been surprisingly found that the new salts
according to the present invention are much more soluble in
water than the corresponding pyridobenzothiazine
30 hydrochlorides prepared up to the present time, and some of
them demonstrate, when in solution, pH values more
compatible with human use in collyria, ointments and
solutions for parenteral use.

In this respect, whereas the water solubility of the
35 hydrochloride is generally between 5 and 20 mg/ml, the
solubility for example of the corresponding sulphonates is
between 80 and 100 mg/ml and that of the corresponding
gluconates is between 350 and 400 mg/ml.



In particular, the solubility of the hydrochloride of
° 9-fluoro-10(4'-methyl)piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido
[1,2,3de][1,4]benzothiazine-6-carboxylic acid in water is 8
mg/ml, whereas the solubility of the corresponding
5 methanesulphonate is 87 mg/ml, with a pH of approximately 3,
the solubility of the corresponding gluconate being 360
mg/ml with a pH of about 5.

The antibacterial activity of the salts according to
the present invention is in no way modified by their
10 salification with organic acids. This considerable
solubility increase coupled with the favourable pH value
enables these medicaments to be administered not only orally
but also parenterally and topically, by dissolving the
effective antibacterial dose in a small volume of vehicle.

15

20

25

30

35



In particular, the preparation of these medicaments for parenteral use in small vials is a great advantage in terms of the local and psychological toleration of the patient.

5 Parenteral therapy is very useful in the case of patients affected by gastrointestinal disturbance, and in the case of hospitalised patients. The particularly high pH of certain salts, such as the gluconic acid salt, enables them to also be used in special formulations as collyria and ointments.

10 The pyrido-benzothiazine salts according to the present invention are prepared by dissolving the pyrido-benzothiazine, and in particular 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3
15 de][1,4]benzothiazine-6-carboxylic acid, in suitable solvents such as chlorobenzene, toluene, xylene or water, and reacting the solution with an equimolar quantity of an organic acid such as methanesulphonic acid, ethanesulphonic acid, n-dodecanesulphonic acid, p-toulenesulphonic acid, 1-octadecanesulphonic acid, 2-chloro-ethanesulphonic acid,
20 2-bromo-ethanesulphonic acid, 3-hydroxy-propanesulphonic acid, citric acid, malonic acid, gluconic acid, malic acid, lactic acid and L-tartaric acid.


Processes for preparing pyrido-benzothiazines, which are the starting substance for the new salts claimed herein,
25 have been described in a previous patent of the present applicant (European patent application 85101881.2). The described processes all pass through a key intermediate, namely 7-fluoro-8-chloro-3,4-dihydro-2H-1,4-benzothiazine (III).

30 We have now discovered a new process, forming a further subject of the present invention, which enables said intermediate (III) to be prepared with particularly high yields, to thus allow the new salts according to the invention to be obtained more conveniently on an industrial
35 scale.


It is however apparent that the new pyrido-benzothiazine salts can also be prepared by preparing the intermediate by known processes.



A second subject of the present invention is therefore a process for preparing pyrido-benzothiazines of formula



10 in which Y is a nitrogenated cyclic base radical of 5 or 6 atoms, and R' is H or C₁-C₆ alkyl, and in particular a new process which enables the compound of formula




20 or its salts with organic acids to be prepared in an industrially economical manner by way of the intermediate of formula



30 in which X is halogen and R' is as heretofore defined.

The intermediate of formula (III) is prepared in an industrially economical manner essentially starting from 2,3,4-trichloronitrobenzene, by cyclisation of a 2-fluoro-3-chloro-4-mercapto derivative of the aminobenzene
35 prepared from it.

Schematically the new process can be represented as follows:



in which R is H, $-\text{CH}_2-\text{COOET}$, $-\text{CH}_2-\text{CH}_2-\text{OH}$ or $-\text{CH}_2-\text{CH}_2\text{Br}$.

The key passage of this process is the preparation of 2,4-difluoro-3-chloronitrobenzene (B) from 2,3,4-trichloronitrobenzene, a compound available industrially at low cost.

The 2,3,4-trichloronitrobenzene, easily obtainable by nitrating the 1,2,3-trichlorobenzene, is reacted with dried KF in DMF or DMSO at a temperature of about 150°C , to give 2,4-fluoro-3-chloro-nitrobenzene (B). From this, according to a first alternative comprising reaction with $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$ at a temperature of between 20 and 50°C in a stream of N_2 , 2-mercapto-3-chloro-4-fluoro-nitrobenzene is obtained, this being a compound (C_1) in which R is H.

This compound is dissolved at ambient temperature in a dipolar aprotic solvent such as DMF or DMSO, ethyl chloroacetate is added and the mixture allowed to react for 2-3 hours at ambient temperature to give ethyl 2-chloro-3-fluoro-6-nitrobenzene-thioglycolate, a compound (C_2) in which R is $-\text{CH}_2-\text{CH}_2-\text{COOET}$.

The same product can also be obtained directly from the 2,4-difluoro-3-chloronitrobenzene (B) by reaction with ethyl thioglycolate in DMF at ambient temperature. The thioether (C_2) is then reduced and simultaneously cyclised to give 7-fluoro-8-chloro-2H-1,4-benzothiazin-3(4H)-one. The reaction is conducted in acetic acid in the presence of

concentrated HCl, using Fe powder as reducing agent, this being added slowly to the mixture in such a manner that the temperature does not rise above 35°C.


5 The benzothiazinone is reduced to benzothiazine preferably by means of metal hydrides such as AlH_3 , LiAlH_4 , NaBH_4 and the like in a suitable organic solvent at ambient temperature.

10 According to an alternative procedure, the 2,4-fluoro-3-chloronitrobenzene (B) is reacted with mercaptoethanol under controlled conditions to arrive at the formulation of 3-chloro-4-fluoro-2-(2-hydroxyethyl) mercaptonitrobenzene (C_3), which by reduction with iron in hydrochloric acid forms 3-chloro-4-fluoro-2-(2-hydroxyethyl) mercaptoaniline (D_1). From this latter, by nucleophilic
15 substitution of the hydrobromic acid, 3-chloro-4-fluoro-2-(2-bromoethyl)mercaptoaniline (D_2) is obtained which by heating with soda in ethanol, cyclises to 8-chloro-7-fluoro-3,4-dihydro-2H-1,4-benzothiazine (III).

20 In both cases the benzothiazine obtained is purified by dissolving in an organic solvent and precipitating as the hydrochloride with gaseous HCl.

25 The process for preparing the key intermediate when carried out in this manner gives an overall yield of 40%, compared with a maximum yield of 25% obtained by the previously described process (a) and a maximum yield of 20% obtained by the previously described process (b) (European patent application 85101881.2).

30 The further steps of the process up to the preparation of the pyrido-benzothiazines of formula (I) are conducted in accordance with the scheme given hereinafter, in which the intermediate (III) is converted in a single passage into the acid (IV) which, by oxidation to the corresponding sulphoxide, nucleophilic substitution with YH amines and
35 reduction, gives the compounds (I).



The operating conditions are described in detail in Example 3.

The pyrido-benzothiazines obtained in this manner, and in particular 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid (II), are dissolved in a suitable organic solvent, preferably chosen from the group consisting of chlorobenzene, toluene and xylene, and are reacted with an equimolar quantity of an organic sulphonic acid of formula RSO_3H , preferably chosen from the group consisting of methanesulphonic acid, ethanesulphonic acid, n-dodecanesulphonic acid, p.toluenesulphonic acid, 1-octadecanesulphonic acid, 2-chloro-ethanesulphonic acid, 2-bromo-ethanesulphonic acid and 3-hydroxy-propanesulphonic acid, or a carboxylic acid preferably chosen from the group consisting of citric acid, malonic acid, gluconic acid, malic acid, lactic acid and tartaric acid.


Some practical preparation examples are given hereinafter by way of non-limiting illustration only, in order to allow the new salts according to the invention to be more easily reproduced.

EXAMPLE 1

Preparation of 7-fluoro-8-chloro-3,4-dihydro-2H-1,4-benzothiazine.



A - Preparation of




(B)

30 g (0.132 moles) of 2,3,4-trichloronitrobenzene (A) are dissolved in 100 ml of DMF, 23 g (0.39 moles) of potassium fluoride are added, and the mixture allowed to react for 16 hours at 150°C.

Chromatography (benzene/hexane 3/7) is used to check when the reaction has terminated, after which water is added and the mixture distilled with steam. The distillate is extracted with CH_2Cl_2 to obtain 19.5 g of a yellowy solid. Yield 75%. M.P. 44-46°C.

B - Preparation of



(C₁)

16.84 g (0.0758 moles) of sodium sulphide nonahydrate are added in portions, over a period of about 30-40 minutes, to 13.47 g (0.07 moles) of compound (B) dissolved in 65 cc of DMF and kept under an N_2 stream, the temperature being maintained at about 20-25°C.


When the addition is complete, the mixture is left under agitation at ambient temperature for about 1 hour to enable the reaction to go to completion.

The mixture is poured into iced water, acidified with 2N HCl to about pH 3, and the solid obtained is filtered off and well squeezed. 12.3 g are obtained with a yield of 85%.

The product is used without further purification for the next reaction. A portion of solid is purified by silica gel chromatography using benzene/AcOH 8/2 as eluent to obtain a yellowy semisolid with the following characteristics: IR (nujol): 2.560 cm^{-1} (v S-H), 11.335 and 1.570 cm^{-1} (v N=O); $^1\text{H-NMR}$ (CDCl_3 -TMS) δ ppm: 5.28

(1H, s, S-H), 7.05 (1H, m, C₅-H), 8.2 (1H, m, C₆-H).

C - Preparation of



(C₂)

5 g (0.024 moles) of compound (C₁) are dissolved at ambient temperature in 100 cc of DMF under magnetic agitation, and 28 ml (0.027 moles) of ethyl chloroacetate are added.

The mixture is left under agitation at ambient temperature, the progress of the reaction being checked by ~~TLC~~ TLC (petroleum ether/ethyl acetate 85/15) on samples withdrawn at predetermined time intervals. After 3 hours the starting compound has completely disappeared.

The mixture is poured into water, extracted with CH₂Cl₂ and the organic extract washed several times with water.

The methylene chloride is dried over Na₂SO₄, filtered and evaporated to obtain 5.1 g of crude product which is used unpurified in the next reaction.


¹H-NMR (CDCl₃-TMS) δ ppm: 1.2 (3H, t, OCH₂CH₃), 3.73 (2H, s, -S-CH₂), 4.15 (2H, q, O-CH₂), 7.32 (1H, m, C₅-H), 7.65 (1H, m, C₆-H).

Alternatively: 2g (0.01 moles) of compound (B) are dissolved in 20 cc of DMF, 1.2 ml (0.011 moles) of ethyl thioglycolate are added, and the mixture allowed to react at ambient temperature for 3 hours.

On termination the mixture is poured into water and extracted with CH₂Cl₂ to obtain 2.2 g of product (C₂) in mixture with a small quantity of para-substituted isomer.



D - Preparation of




10 0.5 g (0.0017 moles) of compound (C₂) are dissolved in 3.5 ml of glacial acetic acid and 0.17 ml of 36% hydrochloric acid are added.

15 While maintaining the mixture under magnetic agitation, 400 mg (0.007 moles) of powdered iron are added in portions, the addition being regulated in such a manner that the temperature does not rise above 35°C. When the addition is complete, the mixture is left at ambient temperature for 2 hours and then filtered through celite to remove any iron residues, and washed well with cold water, hot water and finally with chloroform.

20 After separation, the organic phase is dried over Na₂SO₄, filtered and the solvent evaporated.

In this case the intermediate compound (D) is not isolated, but instead 310 mg of pure product (E) are obtained directly with a yield of 83.66%. M.P. 193-196°C.

25 E - Preparation of



165 mg (0.00076 moles) of compound (E) are suspended in 30 ml of anhydrous THF and subjected to magnetic agitation. 0.033 g (0.0009 moles) of LiAlH₄ are added in portions and the mixture left at ambient temperature for 2 hours. On termination of the reaction small quantities of methanol are added to destroy the hydride, followed by water. The mixture is extracted with chloroform, the organic phase washed with water, dried over Na₂SO₄, and the solvent



5/SLV

evaporated.


125 mg of a yellowy oil are obtained, equivalent to a yield of 80%.

¹H-NMR (CDCl₃-TMS) δ ppm: 3.0 (2H, m, -CH₂-N),
5 3.45 (2H, m, CH₂-2S), 3.8 (1H, s, N-H), 6.15 (1H, m, C₅-H), 6.52 (1H, m, C₆-H).

EXAMPLE 2

Second method for preparing 7-fluoro-8-chloro-3,4
10 -dihydro-2H-1,4-benzothiazine (III)

F - Preparation of



(C₃)


117 g (0.6 moles) of compound (B) and 46.8 g (0.6 moles) of mercaptoethanol are added to 300 ml of ethanol, the solution cooled to 0°C and 87 ml (0.63 moles) of triethylamine
20 dripped slowly in, maintaining the temperature around 0°C. On termination of the addition the mixture is left under agitation at that temperature for about 1 hour (TLC check, CH₂Cl₂/AcOEt 9/1), the solvent evaporated, the product
25 145 g of a yellow-orange oil are obtained from the organic phase after drying and evaporation.

Yield 96%.

¹H-NMR (CDCl₃-TMS) δ ppm: 2.43 (1H, t, O-H), 2.15
(2H, m, CH₂OH), 3.75 (2H, m, S-CH₂), 7.21 (1H, m,
30 C₅-H), 7.59 (1H, m, C₆-H).

IR (film): 1.360 and 1.530 cm⁻¹ (ν N=O).

G - Preparation of



(D₁)




145 g (0.578 moles) of compound (F) are dissolved in 300 ml of ethanol, and 430 cc of 30% HCl are gradually added in such a manner that the mixture temperature reaches 40-45°C. 97 g (1.73 g.atom) of powdered iron are added in portions while maintaining the temperature around this value. On completion of the addition, the mixture is left under agitation for about 30 minutes and the termination of the reaction checked by TLC (CH₂Cl₂/AcOEt 9/1). The small quantity of unreacted iron is then filtered off, the ethanol evaporated under vacuum and 70 g (0.85 moles) of sodium acetate in water added. This operation results in the separation of an oil, which is extracted with CH₂Cl₂. 128 g (quantitative yield) of an oily residue having the following characteristics are obtained from the organic phase after drying and evaporation:

¹H-NMR (CDCl₃-TMS) δ ppm: 2.93 (2H, m, CH₂OH), 3.60 (2H, m, S-CH₂), 4.00 (3H, s, NH₂ and OH), 6.58 (1H, m, C₆-H), 6.93 (1H, m, C₅-H).


IR (film): bands due to the nitro group disappear.

H - Preparation of



128 g (0.578 moles) of compound (D₁) are suspended in 320 ml of 47% HBr and heated to about 120°C for 4-5 hours. On termination of the reaction (TLC check with toluene/AcOEt 2/1), about 300 ml of HBr are distilled off under reduced pressure to obtain 300 g of residue containing aniline hydrobromide, ^{derivative} which is used as such for the next reaction.

L - Preparation of



(III)



300 g of product (D₂) suspended in 300 ml of ethanol are heated to 50-60°C until completely dissolved, and concentrated NaOH is added until alkaline pH persists. The mixture is heated to 70-75°C for about 2 hours, the ethanol evaporated under vacuum and the product extracted with CH₂Cl₂. 95 g are obtained (yield 80% over two passages of a brown oil which show the same characteristics as the product obtained in Example 1.

10 EXAMPLE 3

Preparation of 10-chloro-9-fluoro-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid

15.8 g of product (III) are treated with 19 ml of ethyl ethoxy-methylenemalonate at 120°C under agitation for 1.5 hours.

55 g of polyphosphoric acid are then added, the mixture raised to a temperature of 160°C and kept at this temperature for 1 hour. On termination it is allowed to cool to 120°C, water is added, and the mixture allowed to react for about 1 hour at a temperature of about 100°C while keeping it continuously under agitation.

It is cooled and the solid formed is filtered off, and washed well with water.

18.6 g of a whitish solid are obtained with a yield of 80%.

¹H-NMR (CF₃COOH-TMS) δ ppm: 3.68 (2H, m, N-CH₂), 5.28 (2H, m, S-CH₂), 8.22 (1H, d, Ce-H, J_{H-F} = 8 Hz), 9.40 (1H, s, C₅-H).

IR (nujol): 3.070 cm⁻¹ (C-H), 1.718 cm⁻¹ (C=O).

U.V. (EtOH) λ_{max} 253, 341 μm.

M.P. 311-313°C.

Preparation of 10-chloro-9-fluoro-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-1-oxido-6-carboxylic acid.

15 g of the intermediate obtained heretofore are suspended in 400 cc of AcOH and 6.7 cc of 33% H₂O₂ diluted in 100 cc of AcOH are added. The mixture is allowed to react at 50°C for 20 hours, on termination of which it is

cooled and the insoluble solid filtered off.

14 g of a whitish solid are obtained, equivalent to a yield of 90%.

M.P. 294-298°C.

5 $^1\text{H-NMR}$ ($\text{CF}_3\text{COOH-TMS}$) δ ppm: 8.74 (1H, d, $\text{C}_6\text{-H}$, $J_{\text{H-F}} \approx 7$ Hz), 9.7 (1H, s, $\text{C}_5\text{-H}$).
IR (nujol): 1.049 cm^{-1} , 1.029 cm^{-1} .
UV (EtOH) λ_{max} 224, 270, 354 μm .

10 Preparation of 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid hydrochloride.

16 cc of methyl piperazine are added to 6.5 g of the aforesaid sulfoxide suspended in 100 cc of DMF, the temperature is raised to 100-105°C to obtain complete
15 dissolution, and the solution kept under agitation for 45 minutes at 90-95°C.

The solvent is evaporated and the residue taken up in ethanol to provide 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-
20 1-oxido-6-carboxylic acid with a yield of 8 %.

$^1\text{H-NMR}$ ($\text{CF}_3\text{COOH-TMS}$) δ ppm: 3.3 (3H, d, N-CH_3), 3.9 (10H, m, N-H_2), 5.2 (2H, m, S-CH_2), 8.77 (1H, d, $\text{C}_6\text{-H}$, $J_{\text{H-F}} \approx 10.5$ Hz), 9.68 (1H, s, $\text{C}_5\text{-H}$).

25 Percentage analysis:

Theoretical:	C	53.82%	H	4.78%	N	11.07%
Found:	C	53.34%	H	4.65%	N	10.82%

This latter product can then be reduced to finally
30 obtain compound (II). 5 g of the compound obtained as described are suspended in 250 cc of DMF, the solution cooled to 0-5°C with an ice and salt bath and 4 cc of PCl_3 dripped slowly in. The mixture is allowed to react cold for 15 minutes, 150 cc of water are then added to extinguish the
35 excess of PCl_3 , and the mixture kept under agitation at ambient temperature for about 1 hour.

The solvent is evaporated, the residue taken up in EtOH and the insoluble solid obtained is filtered off to give a yield of 93%.

The 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid hydrochloride can be crystallised under hot conditions from a mixture of EtOH/H₂O in the proportion 7/3.

M.P. 315-320°C.

¹H-NMR (CF₃COOH-TMS) δ ppm: 3.2 (3H, d, N-CH₃), 3.8 (10H, m, N-CH₂), 5.15 (2H, m, CH₂-S), 8.18 (1H, d, C₆-H), J_{H-F} ≈ 10.5 Hz), 9.4 (1H, s, C₅-H).
UV (H₂O) λ max 245 μm and 296 μm.

EXAMPLE 4

Preparation of 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid methanesulphonate.

1.2 cc of methanesulphonic acid are added to 2.16 g of compound (II) suspended in 100 cc of chlorobenzene. The mixture is heated to 130°C and left to react for 1 hour. On termination of the reaction it is cooled and the chlorobenzene decanted. The yellow oily residue is taken up in acetone to obtain 2.5 g of yellowy solid equivalent to a yield of 91%.

The product can be crystallised from an EtOH/H₂O 75/25 mixture.

¹H-NMR (CF₃COOH-TMS) δ ppm: 9.38 (1H, d, C₅-H), 8.2 (1H, d, C₆-H, J_{HF} ≈ 10.5 Hz), 5.12 (2H, m, S-CH₂), 3.7 (13H, m).

Percentage analysis:

Theoretical:	C	47.05%	H	4.82%	N	9.14%
Found:	C	46.85%	H	4.75%	N	8.95%

M.P. 339-341°C.

EXAMPLE 5

Using the method described in Example 1, other derivatives were prepared, namely:

9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid ethanesulphonate.

$^1\text{H-NMR}$ ($\text{CF}_3\text{COOH-TMS}$) δ ppm: 9.35 (1H, s, $\text{C}_5\text{-H}$), 8.15 (1H, d, $\text{C}_e\text{-H}$, $J_{\text{HF}} \approx 10$ Hz), 5.12 (2H, m, S-CH_2), 3.63 (15H, m), 1.5 (3H, t, $\text{CH}_3\text{-CH}_2$).

5 Percentage analysis:

Theoretical:	C	48.19%	H	5.11%	N	8.87%
Found:	C	47.66%	H	5.05%	N	8.72%

M.P. 342-344°C.

10 9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid p.toluene-sulphonate

$^1\text{H-NMR}$ ($\text{CF}_3\text{COOH-TMS}$) ppm: 9.35 (1H, s, $\text{C}_5\text{-H}$), 8.12 (1H, d, $\text{C}_e\text{-H}$, $J_{\text{HF}} 10.5$ Hz), 7.82 (2H, d, H_2 and H_6 , p-toluenesulphonic acid), 7.32 (2H, d, H_3 and H_5 , p-toluenesulphonic acid), 5.12 (2H, m, S-CH_2), 3.60 (13H, m), 2.5 (3H, s, CH_3CH_2).

Percentage analysis:

20 Theoretical:	C	53.82%	H	4.89%	N	7.84%
Found:	C	53.68%	H	4.82%	N	7.74%

M.P. 275-278°C.

25 9-fluoro-10[N-piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid methanesulphonate

Percentage analysis:

Theoretical:	C	45.83%	H	4.52%	N	9.43%
Found:	C	45.71%	H	4.48%	N	9.45%

30 M.P. 343-345°C.

9-fluoro-10[N-piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid ethanesulphonate

35 Percentage analysis:

Theoretical:	C	47.05%	H	4.83%	N	9.14%
Found:	C	46.90%	H	4.79%	N	9.10%

M.P. 348-349°C.

EXAMPLE 6

Preparation of salts of 9-fluoro-10[N-(4'-methyl)
piperazinyll]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3
de][1,4]benzothiazine-6-carboxylic acid with organic
5 carboxylic acids.

General example:

0.5 g of 9-fluoro-10[N-(4'-methyl)piperazinyll]-7-oxo-2,
10 3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic
acid are suspended in 10 cc of H₂O, an equimolar quantity
of the chosen organic acid is added, the mixture heated to
40-50°C for 2 hours and then left under agitation at ambient
15 temperature overnight. On termination, the insoluble
product is filtered off or the solution lyophilised.

Salt with gluconic acid

M.P. 340-342°C.

Solubility in H₂O: 0.36 g/ml

pH 5.07-5.10

20 Percentage analysis:

Theoretical: C 49.37% H 5.40% N 7.51%

Found: C 49.08% H 5.33% N 7.36%

Salt with malonic acid

25 M.P. 288-289°C.

Solubility in H₂O: 3 mg/ml

pH 4.22

Percentage analysis:

Theoretical: C 52.61% H 4.62% N 8.76%

Found: C 52.48% H 4.53% N 8.46%

30

Salt with citric acid

M.P. 278-280°C.

Solubility in H₂O: 2.7 mg/ml

pH 3.99-4.00

Percentage analysis:

35 Theoretical: C 49.73% H 4.72% N 7.56%

Found: C 49.86% H 4.70% N 7.53%

Salt with L-tartaric acid

M.P. 292-294°C.

Solubility in H₂O: 6 mg/ml

pH 4.09-4.10

Percentage analysis:

5	Theoretical:	C	49.12%	H	4.71%	N	8.18%
	Found:	C	49.05%	H	4.67%	N	8.10%

The following pharmaceutical formulations were prepared:

10 - capsules containing 25, 50, 100, 200, 300, 400 mg of
9-fluoro-10[N-(4'-methyl)piperazinyl]-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic methane
sulphate with suitable diluents and excipients.

15 - tablets containing 25, 50, 100, 200, 300, 400 mg of
methanesulphonate or gluconate with suitable diluents and
excipients.

20 - vials containing 25, 50, 100, 200, 300, 400 mg of
methanesulphonate or gluconate together with the required
quantity of water.

- collyria containing 0.05-2% of gluconate in water.

- gluconate-based ointments with suitable excipients.

25

30

35

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Highly water-soluble, antibacterially active organic acid salts of pyridobenzothiazines wherein the pyridobenzothiazine is 9-fluoro-10[N-(4'-methyl)piperazinyl]
5 -7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine -6-carboxylic acid, wherein the organic acid is a sulphonic acid chosen from the group consisting of methanesulphonic acid, ethanesulphonic acid, n-dodecanesulphonic acid, p.toluenesulphonic acid, 1-octadecanesulphonic acid,
10 2-chloroethanesulphonic acid, 2-bromoethanesulphonic acid and 3-hydroxy-propanesulphonic acids or, wherein the organic acid is a carboxylic acid chosen from the group consisting of citric acid, malonic acid, gluconic acid, malic acid, lactic acid and L-tartaric acid.

15

2. A process for preparing highly water-soluble, antibacterially active pyrido-benzothiazine salts, as claimed in claim 1 characterised in that the chosen pyrido-benzothiazine is dissolved in a solvent chosen from
20 the group consisting of chlorobenzene, toluene and xylene, with an equimolar quantity of an organic acid.

3. A process as claimed in claim 2, wherein the pyrido-benzothiazine is 9-fluoro-10[N-(4'-methyl)
25 piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido[1,2,3 de][1,4]benzothiazine-6-carboxylic acid.

4. A process as claimed in claims 2 and 3, wherein the organic acid is a sulphonic acid chosen from the group
30 consisting of methanesulphonic acid, ethanesulphonic acid, n-dodecanesulphonic acid, p.toluenesulphonic acid, 1-octadecanesulphonic acid, 2-chloro-ethanesulphonic acid, 2-bromo-ethanesulphonic acid and 3-hydroxy-propanesulphonic acid.

35



5. A process as claimed in claims 2 and 3, wherein the organic acid is a carboxylic acid chosen from the group consisting of citric acid, malonic acid, gluconic acid, malic acid, lactic acid and L-tartaric acid.

5

6. A process as claimed in claims 2 and 3, wherein the pyrido-benzothiazine dissolved in solution is prepared by way of the intermediate 7-fluoro-8-chloro-3,4-dihydro-2H-1,4-benzothiazine (III), as hereinbefore described.

10

7. A process as claimed in claim 6, wherein the intermediate (III) as hereinbefore described is obtained by reacting the 2,3,4-trichloronitrobenzene with KF to give 2,4-fluoro-3-chloro-nitrobenzene, this is converted by Na₂S into 2-mercapto-3-chloro-4-fluoro-nitrobenzene, which is converted by means of ethyl chloroacetate into 2-chloro-3-fluoro-6-nitrobenzenethioglycolate, which is reduced to 3-fluoro-6-amino-benzenethioglycolate and simultaneously cyclised to benzothiazinone, which is reduced finally to benzothiazine (III) as hereinbefore described by means of metal hydrides, wherein the metal hydrides are selected from the group AlH₃, LiAlH₄ and NaBH₄.

25


30

35




8. A process as claimed in claim 6, wherein the intermediate (III) as hereinbefore described is obtained by reacting the 2,3,4-trichloronitrobenzene with KF to give 2,4-fluoro-3-chloronitrobenzene, which is reacted with mercaptoethanol to give 3-chloro-4-fluoro-2-(2-hydroxyethyl)-mercaptobenzene, this being reduced to 3-chloro-4-fluoro-2-(2-hydroxyethyl)-mercapto-aniline, which is transformed by HBr into the corresponding 2-bromo ethyl derivative which is cyclised to benzothiazine (III).

9. A process as claimed in claims 6 and 7, wherein the 2-fluoro-3-chloro-4-mercapto derivative of formula



which is R is CH₂COOEt is prepared and is simultaneously cyclised by reduction of the corresponding nitro derivatives with Fe in acetic acid in the presence of hydrochloric acid, the benzothiazinone obtained in this manner being reduced to benzothiazine (III) as hereinbefore described by a metal hydride, wherein the metal hydride is selected from the group AlH₃, LiAlH₄, NaBH₄.

10. A process as claimed in claims 6 and 8, wherein the 2-fluoro-3-chloro-4-mercapto derivative of formula



in which R is CH₂-CH₂Br is cyclised to benzothiazine (III) by means of soda in ethanol.

11. A method of preparing a therapeutic composition possessing antibacterial activity comprising admixing an organic acid salt of a pyrido-benzothiazine as claimed in claim 1 with a pharmaceutically acceptable carrier.

5

12. A method of preparing a therapeutic composition possessing antibacterial activity comprising admixing an organic sulphonic acid salt of a pyrido-benzothiazine as claimed in claim 1 with a pharmaceutically acceptable carrier.

10

13. A method of preparing a therapeutic composition possessing antibacterial activity comprising admixing an organic carboxylic acid salt of a pyrido-benzothiazine as claimed in claim 1 with a pharmaceutically acceptable carrier.

15

14. A pharmaceutical product containing an organic acid salt of a pyrido-benzothiazine as claimed in claim 1 and a carrier therefore.

20

15. A organic acid salt of a pyrido-benzothiazine substantially as herein described with reference to any one of Examples 4 to 6.

25

16. A process of preparing a pyrido-benzothiazine salt substantially as herein described with reference to any one of Examples 4 to 6.

30

DATED this 18th day of June, 1990

MEDIOLANUM FARMACEUTICI S.r.l.

35

By their Patent Attorney
GRIFFITH HACK & CO.